Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic lethality strategies to treat relevant cancers. …
Patrys' says preclinical data supports synthetic lethality mechanism
March 15, 2023 Australian Biotech
Latest Video
New Stories
-
The risk to patients of this institution getting too close to the sun
May 25, 2026 - - Latest News -
Pharmacy Guild urges immediate funding for pharmacy to vaccinate in response to outbreak
May 24, 2026 - - Latest News -
AusBiotech launches survey in response to Budget’s 'blind spot' on R&D impact
May 24, 2026 - - Australian Biotech -
Like rearranging deck chairs on the Titanic. The ship is still going to sink
May 23, 2026 - - Latest News -
Merck funds Indigenous STEM leaders at Macquarie University
May 22, 2026 - - Latest News -
The sharper language will need to be accompanied by even sharper actions
May 22, 2026 - - Latest News -
Industry chiefs want united front as agreement negotiations get underway
May 22, 2026 - - Latest News